Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 19/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21277973 | 0.76 | TGFBR1 (0.58) | TGFBR1MAPK14KDR | |
| SCHEMBL20074379 | 0.76 | TGFBR1 (0.58) | TGFBR1MAPK14KDR | |
| SCHEMBL29156790 | 0.69 | NPC1 (0.51) | CCR1CCR8TGFBR1MAPK14THRB | |
| SCHEMBL21277848 | 0.67 | TGFBR1 (0.43) | CCR1CCR8TGFBR1MAPK14THRB | |
| SCHEMBL22930822 | 0.65 | TGFBR1 (0.60) | TGFBR1MAPK14KDR | |
| SCHEMBL1347781 | 0.65 | AVPR1A (0.44) | CCR1CCR8TGFBR1 | |
| SCHEMBL21277829 | 0.64 | TGFBR1 (0.46) | TGFBR1MAPK14THRB | |
| SCHEMBL20158579 | 0.63 | TGFBR1 (0.48) | CCR1CCR8TGFBR1MAPK14KDR | |
| SCHEMBL14576819 | 0.62 | CCR1 (0.37) | CCR1CCR8TGFBR1MAPK14THRB | |
| SCHEMBL20158844 | 0.61 | TGFBR1 (0.50) | CCR1CCR8TGFBR1MAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | CCR1 3095/4885CCR8 1779/4885TGFBR1 1/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | CCR1 3095/4885CCR8 1779/4885TGFBR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.